Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

被引：0
作者：
James G. Wall
Jacqueline K. Benedetti
Mark A. O'Rourke
Ronald B. Natale
John S. Macdonald
机构：
[1] Cabarrus Memorial Hospital,
[2] Southwest Oncology Group Statistical Center,undefined
[3] Ohio State University Health Center,undefined
[4] University of Southern California School of Medicine,undefined
[5] Temple University,undefined
来源：
Investigational New Drugs | 1997年 / 15卷
关键词：
hepatocellular carcinoma; topotecan; phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hepatocellular carcinoma remains a highly chemoresistant neoplasm. In this study of the topoisomerase I inhibitor topotecan a response rate of 13.9% (95% confidence interval 4.7%–29.5%) was obtained utilizing a five consecutive day bolus infusion schedule. There were no complete responses and the median survival was only eight months. Furthermore, treatment with topotecan produced significant toxicity with two-thirds of patients experiencing life-threatening (grade 4) neutropenia. When used in this dose and schedule, topotecan does not appear to be effective for patients with advanced hepatocellular carcinoma.
引用
收藏
页码：257 / 260
页数：3
相关论文
共 54 条
  • [1] Luporini G(1993)Medical treatment of hepatocellular carcinoma J Surg Oncol Suppl 3 115-118
  • [2] Labianca R(1994)Topoisomerase I inhibitors: topotecan and irenotecan Cancer Treat Rev 20 73-96
  • [3] Pancera G(1989)SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models (Abstract) Proc Amm Assoc Cancer Res 30 623-345
  • [4] Creemers GJ(1992)A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days Anti-Cancer Drugs 3 337-656
  • [5] Lund B(1992)Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor J Clin Oncol 10 647-undefined
  • [6] Verweij J(1991)Phase I and clinical pharmacologic study of intravenous topotecan (T) (Abstract) Proc Am Soc Clin Oncol 10 104-undefined
  • [7] Johnson RK(1991)A phase I trial of topotecan (TOPO) administered by a 24-hour infusion (Abstract) Proc Amer Assoc Cancer Res 32 206-undefined
  • [8] McCabe FL(undefined)undefined undefined undefined undefined-undefined
  • [9] Faucette LF(undefined)undefined undefined undefined undefined-undefined
  • [10] Hertzberg RP(undefined)undefined undefined undefined undefined-undefined
123456